Stock Price & Analysis

Based on the provided data and current market conditions, here's a comprehensive analysis of GEHC stock:

Technical Analysis

The stock is currently trading at $87.085 during regular market hours, showing a -0.63% decline. The stock is trading between its Fibonacci support of $86.66 and pivot point of $88.36, suggesting a consolidation phase.

Fundamental Strength

GE HealthCare demonstrates solid fundamentals with:

• RSI at 56.89, indicating balanced momentum
• MACD at 1.36, suggesting positive trend momentum
• Trading above its 20-day SMA of $86.97, indicating short-term bullish sentiment

Recent Developments

• The company is investing $138 million to expand its Irish manufacturing facility, which will increase production capacity by 25 million patient doses annually by 2027
• Analysts expect Q4 2024 EPS of $1.26, representing a 6.8% year-over-year growth
• Jefferies recently upgraded GEHC to Strong Buy with a price target of $103, citing attractive valuation at 17-18x 2025 earnings

Analyst Consensus The stock maintains a Strong Buy consensus with:

• 12 Strong Buy ratings
• 5 Hold ratings
• 1 Strong Sell rating Average price target: $97.33, implying a 14.9% upside potential

Recommendation Based on the technical setup, fundamental strength, and analyst consensus, GEHC presents a buying opportunity at current levels. The stock's position near Fibonacci support with positive MACD suggests a favorable risk-reward ratio. The company's expansion plans and expected earnings growth provide additional upside catalysts.

Based on the provided data and market analysis, here is the price prediction for GEHC stock in 2025:

GE Healthcare Technologies (GEHC) is expected to reach $97-100 by the end of 2025, representing a ~12% upside from current levels, driven by strong analyst consensus and expanding medical imaging business. The company's recent $138 million investment in manufacturing expansion in Ireland to boost production capacity by 25 million more patient doses annually demonstrates solid growth trajectory. The stock maintains a "Strong Buy" rating from Wall Street analysts with a consensus price target of $98.45.

The S1 support level for GEHC Stock is $86.61 ,The R1 resistant level for GEHC Stock is $90.

As of the end of day on 2025-02-11, the price of GEHC Stock was $86.97.

The target price for GEHC Stock according to analyst rating is 100.00, with the highest price target at 105.00 and the lowest at 96.00. Analysts have a Strong Buy rating on GEHC Stock overall.

The market cap of GEHC is $39.7B.

Based on the provided data, let's analyze if GEHC is overvalued:

Valuation Analysis GEHC's current P/E ratio of 25.7x is moderately high compared to the healthcare equipment industry average, suggesting a premium valuation.

Technical Analysis The stock is currently trading at $87.09, showing a slight decline of 0.63% in today's regular market session.

Growth & Profitability The company maintains healthy margins with an EV/EBITDA of 14.23x, indicating reasonable operational efficiency.

Analyst Perspective Piper Sandler maintains a Buy rating with a $97 price target, suggesting approximately 11% upside potential from current levels.

Market Position GE Healthcare demonstrates strong market presence in medical technology and digital solutions, particularly in imaging, diagnostics, and patient monitoring systems.

Based on these metrics and analysis, GEHC appears fairly valued at current levels, supported by its strong market position and analyst confidence, though trading at a slight premium to industry averages.

GE HealthCare Technologies Inc. is a medical technology, pharmaceutical diagnostics, and digital solutions company. It develops, manufactures, and markets a portfolio of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients. Its segments include Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a comprehensive portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its Ultrasound segment includes ultrasound medical devices and solutions with a portfolio of continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment portfolio is comprised of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment is comprised of two business lines: contrast media and molecular imaging.

Based on the provided data and analysis, here is the price prediction for GEHC stock by 2030:

GE Healthcare (GEHC) stock is projected to reach $145-155 by 2030, driven by the company's strong market position in medical imaging and significant investments in manufacturing expansion. The company's recent $138 million investment in Irish factory expansion demonstrates its commitment to meeting growing demand for medical imaging, with global contrast media demand expected to double in the next decade.

The growth trajectory is supported by improving LEAP profitability and expanding services revenue, with analysts maintaining a "Strong Buy" consensus rating and current price targets suggesting near-term upside potential.

GEHC has a total of 51000 employees.